phytomenadione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2843	84-80-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vitamin K1 phytomenadione vitamin K phytonadione phytylmenadione phytylmenaquinone phylloquinone	A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K. Molecular weight: 450.71 Formula: C31H46O2 CLOGP: 11.69 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 34.14 ALOGS: -6.88 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vitamin K1
phytomenadione
vitamin K
phytonadione
phytylmenadione
phytylmenaquinone
phylloquinone

A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

Molecular weight: 450.71
Formula: C31H46O2
CLOGP: 11.69
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 34.14
ALOGS: -6.88
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O
20	mg	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.32 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 18, 2000	FDA	SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	199.64	14.16	67	8775	8090	56275135
International normalised ratio increased	85.49	14.16	64	8778	43977	56239248
Injury associated with device	72.21	14.16	25	8817	3308	56279917
Coagulopathy	57.19	14.16	36	8806	18680	56264545
Cystic fibrosis	56.40	14.16	21	8821	3423	56279802
Multiple organ dysfunction syndrome	51.89	14.16	52	8790	52718	56230507
Renal vascular thrombosis	46.81	14.16	8	8834	46	56283179
Ascites	46.43	14.16	42	8800	37502	56245723
Rheumatoid arthritis	42.84	14.16	5	8837	382599	55900626
Cholestasis	41.16	14.16	34	8808	26879	56256346
Factor V inhibition	37.37	14.16	8	8834	168	56283057
Sepsis	35.59	14.16	72	8770	139768	56143457
Osteochondritis	30.19	14.16	5	8837	23	56283202
Thrombocytopenia	29.85	14.16	66	8776	136158	56147067
Haematemesis	29.47	14.16	29	8813	28729	56254496
Hepatic failure	29.29	14.16	31	8811	33455	56249770
Intestinal dilatation	27.83	14.16	10	8832	1473	56281752
Pancreatitis chronic	26.97	14.16	11	8831	2283	56280942
Superior sagittal sinus thrombosis	26.11	14.16	8	8834	719	56282506
Haemorrhage neonatal	25.98	14.16	5	8837	60	56283165
Haemoptysis	25.77	14.16	26	8816	26534	56256691
Acute hepatic failure	25.46	14.16	21	8821	16557	56266668
Vitamin K deficiency	25.40	14.16	7	8835	433	56282792
Premature baby	24.75	14.16	22	8820	19183	56264042
Transverse sinus thrombosis	24.17	14.16	7	8835	518	56282707
Respiratory failure	23.04	14.16	48	8794	95014	56188211
Drug intolerance	22.19	14.16	7	8835	264811	56018414
Prothrombin time prolonged	21.76	14.16	15	8827	9045	56274180
Cytokine release syndrome	21.51	14.16	16	8826	10859	56272366
Acute kidney injury	20.98	14.16	84	8758	240679	56042546
Activated partial thromboplastin time prolonged	20.90	14.16	13	8829	6599	56276626
Neonatal anuria	20.86	14.16	4	8838	47	56283178
Blood alkaline phosphatase increased	20.74	14.16	28	8814	38917	56244308
Foetal exposure during pregnancy	20.63	14.16	26	8816	33797	56249428
Necrotising enterocolitis neonatal	20.46	14.16	5	8837	192	56283033
Acute respiratory distress syndrome	20.43	14.16	21	8821	21905	56261320
Pain	19.16	14.16	48	8794	663136	55620089
Suspected transmission of an infectious agent via product	19.14	14.16	5	8837	252	56282973
Terminal ileitis	18.76	14.16	6	8836	621	56282604
Hypokalaemia	18.72	14.16	44	8798	94393	56188832
Hepatic encephalopathy	18.07	14.16	14	8828	10096	56273129
Aspartate aminotransferase increased	18.05	14.16	40	8802	82562	56200663
Gamma-glutamyltransferase increased	17.59	14.16	23	8819	30982	56252243
Therapeutic product effect decreased	17.10	14.16	3	8839	169449	56113776
Pelvic fluid collection	17.03	14.16	6	8836	835	56282390
Oligohydramnios	16.99	14.16	11	8831	5983	56277242
HER2 positive breast cancer	16.91	14.16	5	8837	398	56282827
Pulmonary function test decreased	16.50	14.16	9	8833	3582	56279643
Bilirubin conjugated increased	16.29	14.16	8	8834	2565	56280660
Blood bilirubin increased	16.28	14.16	23	8819	33331	56249894
Renal failure	16.24	14.16	46	8796	110454	56172771
Retroperitoneal haematoma	15.83	14.16	8	8834	2725	56280500
Jugular vein thrombosis	15.64	14.16	8	8834	2795	56280430
Pulmonary pain	15.44	14.16	8	8834	2872	56280353
Foetal growth restriction	15.30	14.16	11	8831	7088	56276137
Treatment failure	15.19	14.16	4	8838	170388	56112837
Clostridium difficile infection	15.16	14.16	20	8822	27178	56256047
Drug ineffective	15.08	14.16	84	8758	918905	55364320
Epicondylitis	15	14.16	7	8835	2006	56281219
Pleural effusion	14.99	14.16	38	8804	85442	56197783
Alanine aminotransferase increased	14.76	14.16	40	8802	93622	56189603
Disseminated intravascular coagulation	14.65	14.16	16	8826	17869	56265356
Subdural haematoma	14.55	14.16	14	8828	13485	56269740
Transaminases increased	14.28	14.16	20	8822	28750	56254475
Hepatosplenic candidiasis	14.27	14.16	4	8838	263	56282962
Low birth weight baby	14.19	14.16	10	8832	6248	56276977

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	336.55	15.37	110	10629	5621	31680984
Appendicitis	282.48	15.37	116	10623	11349	31675256
Ascites	245.88	15.37	160	10579	40853	31645752
Cardiogenic shock	211.16	15.37	117	10622	22291	31664314
Stress	183.81	15.37	111	10628	24830	31661775
Multiple organ dysfunction syndrome	183.41	15.37	165	10574	68038	31618567
Infective pulmonary exacerbation of cystic fibrosis	181.68	15.37	72	10667	6412	31680193
Abdominal distension	159.12	15.37	134	10605	50550	31636055
Ventricular fibrillation	113.90	15.37	74	10665	18774	31667831
Hyponatraemia	108.18	15.37	129	10610	73670	31612935
Sepsis	98.86	15.37	181	10558	151748	31534857
Abdominal pain	96.36	15.37	175	10564	145777	31540828
International normalised ratio increased	72.77	15.37	83	10656	45140	31641465
Blood phosphorus increased	70.17	15.37	33	10706	4449	31682156
Toxic epidermal necrolysis	68.22	15.37	55	10684	19469	31667136
General physical health deterioration	67.25	15.37	130	10609	113305	31573300
Constipation	66.19	15.37	136	10603	123855	31562750
Vomiting	52.75	15.37	181	10558	223792	31462813
Cystic fibrosis	45.35	15.37	19	10720	1947	31684658
Hepatic failure	41.12	15.37	53	10686	32649	31653956
Hyper IgE syndrome	39.44	15.37	8	10731	55	31686550
Hyphaema	30.20	15.37	10	10729	530	31686075
Coagulopathy	24.83	15.37	31	10708	18484	31668121
Hyperbilirubinaemia	23.78	15.37	28	10711	15722	31670883
Epileptic encephalopathy	23.35	15.37	6	10733	128	31686477
Nausea	22.77	15.37	180	10559	307767	31378838
Toxicity to various agents	22.72	15.37	17	10722	181470	31505135
Coagulation time prolonged	22.06	15.37	10	10729	1238	31685367
Hepatic encephalopathy	21.80	15.37	25	10714	13646	31672959
Cystic fibrosis related diabetes	21.63	15.37	6	10733	173	31686432
Acute hepatic failure	21.33	15.37	24	10715	12835	31673770
Activated partial thromboplastin time prolonged	20.27	15.37	19	10720	8206	31678399
Drug ineffective	20.09	15.37	68	10671	395505	31291100
Cortical visual impairment	19.53	15.37	4	10735	29	31686576
Pain	18.11	15.37	22	10717	186737	31499868
Myocardial infarction	17.92	15.37	8	10731	113446	31573159
Death	16.95	15.37	64	10675	360505	31326100
Prothrombin time prolonged	16.83	15.37	18	10721	9094	31677511
Restrictive cardiomyopathy	16.83	15.37	7	10732	704	31685901
Dizziness	16.76	15.37	26	10713	199121	31487484
Iatrogenic infection	16.71	15.37	4	10735	63	31686542
Skin candida	16.31	15.37	6	10733	435	31686170
Dysmorphism	15.98	15.37	11	10728	3061	31683544
Product dose omission issue	15.83	15.37	8	10731	105578	31581027
Blood bilirubin increased	15.77	15.37	36	10703	35100	31651505
Off label use	15.69	15.37	183	10556	347091	31339514
Fatigue	15.42	15.37	60	10679	335146	31351459

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	367.95	14.13	109	17287	5571	70905477
Infective pulmonary exacerbation of cystic fibrosis	341.64	14.13	124	17272	12034	70899014
Ascites	288.52	14.13	189	17207	67358	70843690
Appendicitis	269.42	14.13	114	17282	16619	70894429
Multiple organ dysfunction syndrome	234.92	14.13	202	17194	108313	70802735
Cardiogenic shock	211.87	14.13	124	17272	36183	70874865
International normalised ratio increased	140.50	14.13	133	17263	80593	70830455
Sepsis	139.96	14.13	230	17166	244315	70666733
Abdominal distension	139.14	14.13	149	17247	104520	70806528
Stress	124.05	14.13	115	17281	67851	70843197
Ventricular fibrillation	115.94	14.13	76	17320	27035	70884013
Cystic fibrosis	81.86	14.13	33	17363	4248	70906800
Hyponatraemia	76.27	14.13	139	17257	159948	70751100
Blood phosphorus increased	67.34	14.13	33	17363	6737	70904311
Coagulopathy	65.99	14.13	59	17337	33190	70877858
Hepatic failure	64.41	14.13	75	17321	57550	70853498
Abdominal pain	61.56	14.13	204	17192	341923	70569125
Constipation	57.97	14.13	164	17232	252274	70658774
Toxic epidermal necrolysis	57.28	14.13	59	17337	39498	70871550
General physical health deterioration	51.91	14.13	151	17245	235880	70675168
Respiratory failure	41.04	14.13	112	17284	168623	70742425
Pain	38.80	14.13	59	17337	628757	70282291
Activated partial thromboplastin time prolonged	37.25	14.13	29	17367	13476	70897572
Haemoptysis	37.17	14.13	54	17342	51398	70859650
Acute hepatic failure	36.01	14.13	39	17357	27633	70883415
Hepatic encephalopathy	35.70	14.13	35	17361	22083	70888965
Renal vascular thrombosis	34.43	14.13	7	17389	70	70910978
Drug intolerance	33.95	14.13	7	17389	225680	70685368
Cytokine release syndrome	33.92	14.13	37	17359	26430	70884618
Hyperbilirubinaemia	33.28	14.13	34	17362	22534	70888514
Cholestasis	32.79	14.13	49	17347	47823	70863225
Factor V inhibition	32.71	14.13	9	17387	351	70910697
Prothrombin time prolonged	32.65	14.13	29	17367	16161	70894887
Thrombocytopenia	32.28	14.13	130	17266	238980	70672068
Hyphaema	29.23	14.13	10	17386	813	70910235
Vomiting	27.95	14.13	244	17152	592867	70318181
Osteochondritis	27.45	14.13	5	17391	26	70911022
Blood bilirubin increased	27.20	14.13	51	17345	59850	70851198
Drug ineffective	25.76	14.13	131	17265	939621	69971427
Coagulation time prolonged	25.75	14.13	12	17384	2192	70908856
Hyper IgE syndrome	25.60	14.13	8	17388	489	70910559
Transverse sinus thrombosis	23.83	14.13	8	17388	614	70910434
Dizziness	23.65	14.13	49	17347	464092	70446956
Toxicity to various agents	23.38	14.13	36	17360	382136	70528912
Subdural haematoma	23	14.13	32	17364	29266	70881782
Cystic fibrosis related diabetes	22.32	14.13	6	17390	214	70910834
Drug reaction with eosinophilia and systemic symptoms	22.23	14.13	46	17350	57967	70853081
Cortical visual impairment	21.20	14.13	4	17392	26	70911022
Neutropenic colitis	21.03	14.13	14	17382	5100	70905948
Fall	20.88	14.13	49	17347	444047	70467001
Febrile neutropenia	20.68	14.13	102	17294	204216	70706832
Contraindicated product administered	20.60	14.13	4	17392	134608	70776440
Haematemesis	20.26	14.13	40	17356	48757	70862291
Restrictive cardiomyopathy	20.14	14.13	8	17388	990	70910058
Disseminated intravascular coagulation	19.67	14.13	32	17364	33566	70877482
Distal intestinal obstruction syndrome	19.35	14.13	7	17389	671	70910377
Intestinal dilatation	19.32	14.13	10	17386	2290	70908758
Acute kidney injury	19.16	14.13	189	17207	474435	70436613
Vitamin K deficiency	19.01	14.13	7	17389	705	70910343
Sputum increased	18.84	14.13	12	17384	4060	70906988
Therapeutic product effect decreased	18.51	14.13	6	17390	143012	70768036
Epileptic encephalopathy	18.42	14.13	6	17390	419	70910629
Septic shock	18.41	14.13	65	17331	112193	70798855
Joint swelling	18.38	14.13	21	17375	253190	70657858
Product use issue	17.88	14.13	11	17385	179926	70731122
Iatrogenic infection	17.77	14.13	4	17392	67	70910981
Pulmonary function test decreased	17.46	14.13	14	17382	6787	70904261
Pancreatitis chronic	17.21	14.13	11	17385	3743	70907305
Jaundice	17.20	14.13	38	17358	50070	70860978
Escherichia bacteraemia	17.05	14.13	13	17383	5856	70905192
Injury associated with device	16.80	14.13	10	17386	3002	70908046
Superior sagittal sinus thrombosis	16.68	14.13	7	17389	997	70910051
Jugular vein thrombosis	16.55	14.13	11	17385	3999	70907049
Blood alkaline phosphatase increased	16.41	14.13	41	17355	58480	70852568
Tumour lysis syndrome	16.27	14.13	23	17373	21337	70889711
Arthralgia	16.22	14.13	66	17330	503324	70407724
Musculoskeletal stiffness	16.18	14.13	8	17388	147752	70763296
Gait disturbance	16.17	14.13	13	17383	185093	70725955
Transaminases increased	15.41	14.13	35	17361	46983	70864065
HER2 positive breast cancer	15.26	14.13	5	17391	356	70910692
Off label use	15.17	14.13	261	17135	742799	70168249
Acute respiratory distress syndrome	14.98	14.13	32	17364	41222	70869826
Epistaxis	14.79	14.13	57	17339	102570	70808478
Product dose omission issue	14.76	14.13	19	17377	217449	70693599
Heart transplant	14.57	14.13	7	17389	1368	70909680
Nasopharyngitis	14.48	14.13	20	17376	222186	70688862
Lactobacillus test positive	14.41	14.13	3	17393	34	70911014
Discomfort	14.41	14.13	4	17392	105432	70805616
Hepatorenal syndrome	14.30	14.13	10	17386	3947	70907101

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02BA01	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Vitamin K
FDA CS	M0022806	Vitamin K
MeSH PA	D000933	Antifibrinolytic Agents
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
MeSH PA	D018977	Micronutrients
MeSH PA	D014815	Vitamins
FDA PE	N0000175965	Increased Prothrombin Activity
FDA EPC	N0000175966	Warfarin Reversal Agent
FDA PE	N0000175982	Reversed Anticoagulation Activity
FDA EPC	N0000180191	Vitamin K
CHEBI has role	CHEBI:23357	cofactor
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:24020	fat-soluble vitamins
CHEBI has role	CHEBI:75771	Mus musculus metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypocalcemia	indication	5291005
Osteoporosis	indication	64859006	DOID:11476
Factor II deficiency	indication	73975000
Postmenopausal osteoporosis	indication	102447009
Prevention of Neonatal Hemorrhagic Disease	indication
Antibiotic-Induced Hypoprothrombinemia	indication
Neonatal Hemorrhagic Disease	indication
Vitamin K Deficiency Induced Hypoprothrombinemia	indication
Anticoagulant-Induced Prothrombin Deficiency	indication
Obstruction of bile duct	off-label use	30144000
Abetalipoproteinemia	off-label use	190787008	DOID:1386
Constipation	contraindication	14760008	DOID:2089
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
Vitamin E deficiency	contraindication	54137008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Anemia due to enzyme deficiency	contraindication	111577008
Neoplasm of endometrium	contraindication	123844007	DOID:1380
Neoplasm of prostate	contraindication	126906006	DOID:10283
Osteolysis	contraindication	203522001
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160
Malignant tumor of cervix	contraindication	363354003	DOID:4362
Central nervous system depression	contraindication	418072004
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG/ML	PHYTONADIONE	CIPLA	A214596	April 22, 2022	RX	INJECTABLE	INJECTION	Oct. 30, 2022	COMPETITIVE GENERIC THERAPY
1MG/0.5ML	PHYTONADIONE	CIPLA	A214596	April 22, 2022	RX	INJECTABLE	INJECTION	Oct. 30, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	4.82		CHEMBL

External reference:

ID	Source
4017772	VUID
N0000146136	NUI
D00148	KEGG_DRUG
4017772	VANDF
4018981	VANDF
4021719	VANDF
4021911	VANDF
C0031862	UMLSCUI
CHEBI:18067	CHEBI
PQN	PDB_CHEM_ID
CHEMBL1550	ChEMBL_ID
CHEMBL1201519	ChEMBL_ID
DB01022	DRUGBANK_ID
5284607	PUBCHEM_CID
11258	RXNORM
1433	MMSL
15677	MMSL
199215	MMSL
42273	MMSL
5298	MMSL
d03135	MMSL
001038	NDDF
001042	NDDF
63136007	SNOMEDCT_US
65183007	SNOMEDCT_US
66656000	SNOMEDCT_US
74226000	SNOMEDCT_US
D010837	MESH_DESCRIPTOR_UI
D014812	MESH_DESCRIPTOR_UI
177	INN_ID
A034SE7857	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1704	TABLET	5 mg	ORAL	NDA	22 sections
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1704	TABLET	5 mg	ORAL	NDA	22 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9935	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9935	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9969	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9969	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9157	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	18 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9158	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	18 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6882	TABLET	5 mg	ORAL	ANDA	28 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6882	TABLET	5 mg	ORAL	ANDA	28 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	16714-973	TABLET	5 mg	ORAL	ANDA	21 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	16714-973	TABLET	5 mg	ORAL	ANDA	21 sections
MEPHYTON	HUMAN PRESCRIPTION DRUG LABEL	1	21695-168	TABLET	5 mg	ORAL	NDA	21 sections
PHYTONADIONE PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	43598-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
PHYTONADIONE PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	43598-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1753	TABLET	5 mg	ORAL	NDA	20 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4521	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4523	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	19 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	50268-661	TABLET	5 mg	ORAL	NDA authorized generic	20 sections
VITAMIN K1 - PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1536	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	13 sections
VITAMIN K1 PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1537	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-043	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-046	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	52584-240	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5646	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	19 sections
Adult Infuvite Multiple Vitamins for Infusion	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5649	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	17 sections
Adult Infuvite Multiple Vitamins for Infusion	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5649	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	17 sections
Infuvite Adult Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5650	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	20 sections
Adult Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-7862	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	20 sections